Elon Musk’s unique approach to treating depression has sparked interest and controversy alike. Recent reports suggest that the tech mogul occasionally utilizes ketamine, a tranquilizer with hallucinogenic properties, in small doses to alleviate symptoms of depression. Additionally, Musk reportedly indulges in full doses of the popular club drug known as Special K while attending parties. This revelation sheds light on a growing trend within Silicon Valley, where executives explore recreational use of psychedelics to enhance business performance and boost creativity.
According to the Wall Street Journal, witnesses and individuals with direct knowledge have confirmed Musk’s use of ketamine for depression management and the occasional consumption of Special K. Seeking insight from Musk himself, The Post reached out for comment. Interestingly, upon the publication of The Journal’s story, Musk turned to his social media platform to espouse the benefits of ketamine, which has gained popularity as an alternative treatment for depression. Musk believes that while depression may be overdiagnosed in the US, it is indeed a brain chemistry issue for certain individuals. He emphasizes the potential dangers of relying solely on selective serotonin reuptake inhibitors (SSRIs), the commonly prescribed antidepressants, which he feels can “zombify” individuals. Instead, Musk argues that occasional use of ketamine is a superior option, based on his observations among friends.
The potential benefits of ketamine have also caught the attention of Wall Street executives, who reportedly pay $750 to undergo ketamine treatments at an upscale Manhattan clinic. However, Elon Musk is not the only tycoon to allegedly experiment with hallucinogenic substances. The Journal reports that Sergey Brin, co-founder of Google and a close friend of Musk, has admitted to using magic mushrooms. These mushrooms contain psilocybin, a chemical that induces hallucinations and has shown promise in clinical trials for treating depression and other mental health conditions. Brin was unavailable for comment at the time of writing.
The tech industry’s fascination with psychedelics extends beyond personal use. The Journal uncovers a hidden world of tech-centric gatherings and parties where executives hire chemists and even purchase drugs like ecstasy and hallucinogens from dealers. Founders Fund, the prestigious San Francisco-based venture capital firm co-founded by Peter Thiel, is reported to have organized exclusive parties featuring psychedelic drug use. When questioned about this, a spokesperson for Founders Fund expressed support for the potential mental health benefits offered by psychedelics and advocated for their safe and legal availability.
Entrepreneurs like Spencer Shulem, CEO of the startup firm BuildBetter.ai, swear by the benefits of psychedelics. Shulem credits his occasional use of LSD with improving concentration and promoting creative thinking. He believes that ingenuity is necessary to secure venture capital funding and set his company apart from the competition. Despite his personal experiences, Shulem claims that he does not actively encourage LSD use among his employees. His intention is not to promote drug use but rather to highlight his own unique perspective in the tech industry.
In conclusion, Elon Musk’s reported utilization of ketamine for depression treatment and experimentation with Special K at parties has ignited discussion about a larger trend within Silicon Valley. The use of psychedelics among executives is believed to enhance business performance and stimulate creativity. While opinions on the matter differ, it is clear that this topic continues to generate interest among individuals in various industries.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
